LAFUTIDINE

SynDRA canonical compound SYN0026720 — structure-anchored drug synonym record

Clinical phase	Launched
Primary target(s)	HRH2
Mechanism of action	histamine receptor antagonist
Indication	duodenal ulcer disease \| duodenal ulcer disease, peptic ulcer disease (pud) \| peptic ulcer disease (PUD)
Disease area	gastroenterology

All known targets

FRG-8813
laflutidine
protecadin
Lafutidina
FRG 8813
Lafutidine [INN]
(Z)-Lafutidine
Lafutidine [JAN]
Lafutidine free base
rac Lafutidine
Lafutidine [MART.]
Lafutidine [WHO-DD]
Lafutidine, (+/-)-
(Z)-2-((FURAN-2-YLMETHYL)SULFINYL)-N-(4-((4-(PIPERIDIN-1-YLMETHYL)PYRIDIN-2-YL)OXY)BUT-2-EN-1-YL)ACETAMIDE
49S4O7ADLC
118288-08-7 (free base)
2-(furan-2-ylmethylsulfinyl)-N-[(Z)-4-[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxybut-2-enyl]acetamide
Acetamide, 2-[(2-furanylmethyl)sulfinyl]-N-[(2Z)-4-[[4-(1-piperidinylmethyl)-2-pyridinyl]oxy]-2-buten-1-yl]-
UNII-49S4O7ADLC
Protecadin
(+/-)-2-(Furfurylsulfinyl)-N-((Z)-4-((4-(piperidinomethyl)-2-pyridyl)oxy)-2-butenyl) acetamide
CAS-118288-08-7
Laftidine
Stogar
Protecadin (TN)
NCGC00164550-01
N-(4-(4-Piperidinylmethyl)pyridyl-2-oxy)butenyl-2-(furfurylsulfinyl)acetamide
starbld0049801
Lafutidine (JP17/INN)
MLS006011259
SCHEMBL362540
CHEMBL1742461
DTXSID0046434
Lafutidine, >=98% (HPLC)
CHEBI:31759
Lafutidine [INN:JAN:WHO-DD]
HMS3884D03
ACT06288